Literature DB >> 11900250

The development of androgen-independent prostate cancer.

B J Feldman1, D Feldman.   

Abstract

The normal prostate and early-stage prostate cancers depend on androgens for growth and survival, and androgen ablation therapy causes them to regress. Cancers that are not cured by surgery eventually become androgen independent, rendering anti-androgen therapy ineffective. But how does androgen independence arise? We predict that understanding the pathways that lead to the development of androgen-independent prostate cancer will pave the way to effective therapies for these, at present, untreatable cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11900250     DOI: 10.1038/35094009

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  795 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

3.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

4.  Chinese red yeast rice inhibition of prostate tumor growth in SCID mice.

Authors:  Mee Young Hong; Susanne Henning; Aune Moro; Navindra P Seeram; Yanjun Zhang; David Heber
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

5.  Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.

Authors:  Krishna B Singh; Xinhua Ji; Shivendra V Singh
Journal:  Mol Cancer Ther       Date:  2018-07-20       Impact factor: 6.261

6.  shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.

Authors:  Peng Jin; Jinliang Xie; Xiangrong Zhu; Cheng Zhou; Xiang Ding; Luoyan Yang
Journal:  Int Urol Nephrol       Date:  2013-12-11       Impact factor: 2.370

7.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

8.  Negative modulation of androgen receptor transcriptional activity by Daxx.

Authors:  Ding-Yen Lin; Hsin-I Fang; Ai-Hong Ma; Yen-Sung Huang; Yeong-Shiau Pu; Guido Jenster; Hsing-Jien Kung; Hsiu-Ming Shih
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.

Authors:  Kevin A Link; Craig J Burd; Erin Williams; Thomas Marshall; Gary Rosson; Erin Henry; Bernard Weissman; Karen E Knudsen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.

Authors:  Urszula L McClurg; Nay C T H Chit; Mahsa Azizyan; Joanne Edwards; Arash Nabbi; Karl T Riabowol; Sirintra Nakjang; Stuart R McCracken; Craig N Robson
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.